Neoadjuvant concurrent chemoradiotherapy using infusional gemcitabine in locally advanced rectal cancer: A phase II trial.

Introduction: Gemcitabine is a well-known radiosensitizer. Herein, we tested the efficacy and toxicity of preoperative concurrent infusional gemcitabine and radiotherapy in locally advanced rectal cancer.

Patients And Methods: This was a phase II, single-arm trial.

Neglected right diaphragmatic hernia with transthoracic herniation of gallbladder and malrotated left liver lobe in an adult.

Diaphragmatic hernias are commonly encountered in radiological practice, especially in pediatric patients. Delayed presentation of diaphragmatic hernias can occur in children and less frequently in adult patients. We present an extremely rare case of a 15-year-old male patient with recurrent attacks of cholestatic hepatitis who has been misdiagnosed to have primary sclerosing cholangitis and was planned for liver transplantation.

Radiological Findings in Persistent Müllerian Duct Syndrome: Case Report and Review of Literature.

This case involved a 36-year-old adult male who presented with an unusual inguinal hernia in which the uterus and fallopian tubes were identified as contents of the inguinal hernia sac. These findings reflected a rare autosomal recessive developmental syndrome known as PMDS (persistent Müllerian duct syndrome). The diagnosis was established and confirmed via radiological-mainly MRI-investigation.

Pre-operative chemoradiotherapy using capecitabine and cetuximab followed by definitive surgery in patients with operable rectal cancer.

Background: Achieving a high rate of complete pathological response with pre-operative chemoradiotherapy in rectal cancer is an unmet need. We evaluated the efficacy and toxicity of the combination of cetuximab, capecitabine and radiation therapy in the pre-operative setting of localized rectal cancer.

Patients And Methods: Patients with clinically staged T3, T4 or nodepositive rectal cancer were treated with concurrent capecitabine and radiotherapy with weekly cetuximab starting one week before the start of radiation.